Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Diabetes Mellitus
Interventions
DRUG

Insulin Lispro

Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.

DRUG

Exubera

Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.

Trial Locations (63)

13057

Pfizer Investigational Site, East Syracuse

19020

Pfizer Investigational Site, Bensalem

20817

Pfizer Investigational Site, Bethesda

23462

Pfizer Investigational Site, Virginia Beach

23502

Pfizer Investigational Site, Norfolk

27834

Pfizer Investigational Site, Greenville

28557

Pfizer Investigational Site, Morehead City

28625

Pfizer Investigational Site, Statesville

29615

Pfizer Investigational Site, Greenville

31904

Pfizer Investigational Site, Columbus

32205

Pfizer Investigational Site, Jacksonville

32216

Pfizer Investigational Site, Jacksonville

32789

Pfizer Investigational Site, Winter Park

33156

Pfizer Investigational Site, Miami

33401

Pfizer Investigational Site, West Palm Beach

36608

Pfizer Investigational Site, Mobile

38119

Pfizer Investigational Site, Memphis

38133

Pfizer Investigational Site, Bartlett

40213

Pfizer Investigational Site, Louisville

40503

Pfizer Investigational Site, Lexington

45429

Pfizer Investigational Site, Kettering

48532

Pfizer Investigational Site, Flint

50314

Pfizer Investigational Site, Des Moines

53209

Pfizer Investigational Site, Milwaukee

60031

Pfizer Investigational Site, Gurnee

60607

Pfizer Investigational Site, Chicago

63110

Pfizer Investigational Site, St Louis

63141

Pfizer Investigational Site, St Louis

68131

Pfizer Investigational Site, Omaha

72104

Pfizer Investigational Site, Malvern

73103

Pfizer Investigational Site, Oklahoma City

74104

Pfizer Investigational Site, Tulsa

75230

Pfizer Investigational Site, Dallas

75246

Pfizer Investigational Site, Dallas

76012

Pfizer Investigational Site, Arlington

76014

Pfizer Investigational Site, Arlington

77004

Pfizer Investigational Site, Houston

78229

Pfizer Investigational Site, San Antonio

79935

Pfizer Investigational Site, El Paso

80209

Pfizer Investigational Site, Denver

83404

Pfizer Investigational Site, Idaho Falls

92120

Pfizer Investigational Site, San Diego

92610

Pfizer Investigational Site, Foot Hill Ranch

92780

Pfizer Investigational Site, Tustin

93720

Pfizer Investigational Site, Fresno

94904

Pfizer Investigational Site, Greenbrae

96813

Pfizer Investigational Site, Honolulu

96814

Pfizer Investigational Site, Honululu

97701

Pfizer Investigational Site, Bend

98055

Pfizer Investigational Site, Renton

99208

Pfizer Investigational Site, Spokane

35294-307

Pfizer Investigational Site, Birmingham

85006-2850

Pfizer Investigational Site, Phoenix

95032-3739

Pfizer Investigational Site, Los Gatos

94401-3805

Pfizer Investigational Site, San Mateo

06050

Pfizer Investigational Site, New Britain

20010-2934

Pfizer Investigational Site, Washington D.C.

30034-1680

Pfizer Investigational Site, Decatur

21234-4607

Pfizer Investigational Site, Baltimore

02114

Pfizer Investigational Site, Boston

55454-1321

Pfizer Investigational Site, Minneapolis

05201-5018

Pfizer Investigational Site, Bennington

00936-5067

Pfizer Investigational Site, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00348374 - Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes | Biotech Hunter | Biotech Hunter